이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성 또는 불응성 다발성 골수종 환자를 대상으로 한 Talquetamab 연구 (MonumenTAL-1)

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

재발성 또는 불응성 다발성 골수종 대상자에서 인간화 GPRC5D x CD3 이중특이성 항체인 Talquetamab의 임상 1/2상, 최초, 공개 라벨, 용량 증량 연구

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

510

단계

  • 2 단계

확장된 액세스

승인됨 대중에게 판매합니다. 확장 액세스 기록을 참조하세요.

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

  • 네덜란드
      • Amsterdam, 네덜란드, 1081 HV
        • 완전한
        • VU Medisch Centrum
      • Utrecht, 네덜란드, 3584 CX
        • 완전한
        • UMCU
  • 대한민국
      • Jeollanam-do, 대한민국, 58128
        • 완전한
        • Chonnam National University Hwasun Hospital
      • Seoul, 대한민국, 06351
        • 완전한
        • Samsung Medical Center
      • Seoul, 대한민국, 05505
        • 완전한
        • Asan Medical Center
      • Seoul, 대한민국, 03080
        • 완전한
        • Seoul National University Hospital
      • Seoul, 대한민국, 03722
        • 완전한
        • Severance Hospital Yonsei University Health System
      • Seoul, 대한민국, 06591
        • 완전한
        • The Catholic University of Korea Seoul St Marys Hospital
  • 독일
      • Berlin, 독일, 12203
        • 모집하지 않고 적극적으로
        • Charite Campus Benjamin Franklin
      • Heidelberg, 독일, 69120
        • 모집하지 않고 적극적으로
        • Universitaetsklinikum Heidelberg
      • Münster, 독일, 48149
        • 완전한
        • Universitaetsklinikum Muenster
      • Würzburg, 독일, 97080
        • 모집하지 않고 적극적으로
        • Universitatsklinikum Wurzburg
  • 미국
    • Alabama
      • Birmingham, Alabama, 미국, 35294
        • 모병
        • University of Alabama Birmingham
    • Arkansas
      • Little Rock, Arkansas, 미국, 72205
        • 모병
        • University of Arkansas for Medical Sciences
    • California
      • Duarte, California, 미국, 91010
        • 완전한
        • City of Hope
    • Florida
      • Hollywood, Florida, 미국, 33021
        • 모병
        • Memorial Healthcare System
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모병
        • Emory University Winship Cancer Institute
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • 완전한
        • University of Chicago
    • Kentucky
      • Louisville, Kentucky, 미국, 40207
        • 모병
        • Norton Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • University of Michigan Health System
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University School Of Medicine
    • New York
      • New York, New York, 미국, 10023
        • 모병
        • Mount Sinai Medical Center
      • New York, New York, 미국, 10016
        • 모집하지 않고 적극적으로
        • NYU Langone Health
      • Rochester, New York, 미국, 14642
        • 모병
        • University of Rochester Medical Center
    • Oregon
      • Portland, Oregon, 미국, 97213
        • 완전한
        • Providence Portland Medical Center
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 완전한
        • Tennessee Oncology
  • 벨기에
      • Edegem, 벨기에, 2650
        • 완전한
        • UZ Antwerpen
      • Leuven, 벨기에, 3000
        • 모집하지 않고 적극적으로
        • UZ Leuven
      • Liège, 벨기에, 4000
        • 모집하지 않고 적극적으로
        • CHU de Liège - Domaine Universitaire du Sart Tilman
      • Woluwe-Saint-Lambert, 벨기에, 1200
        • 완전한
        • UCL - Saint Luc
  • 스페인
      • Badalona, 스페인, 08916
        • 완전한
        • Hosp. Univ. Germans Trias I Pujol
      • Barcelona, 스페인, 8908
        • 모집하지 않고 적극적으로
        • Inst. Cat. Doncologia-H Duran I Reynals
      • Barcelona, 스페인, 08035
        • 모병
        • Hosp Univ Vall D Hebron
      • Madrid, 스페인, 28041
        • 완전한
        • Hosp. Univ. 12 de Octubre
      • Madrid, 스페인, 28040
        • 완전한
        • Hosp Univ Fund Jimenez Diaz
      • Murcia, 스페인, 30120
        • 모집하지 않고 적극적으로
        • Hosp. Univ. Virgen de La Arrixaca
      • Pamplona, 스페인, 31008
        • 모병
        • Clinica Univ. de Navarra
      • Pozuelo de Alarcón, 스페인, 28223
        • 완전한
        • Hosp. Quiron Madrid Pozuelo
      • Salamanca, 스페인, 37007
        • 모병
        • Hosp Clinico Univ de Salamanca
      • Santander, 스페인, 39008
        • 모병
        • Hosp. Univ. Marques de Valdecilla
      • Seville, 스페인, 41013
        • 모병
        • Hosp. Virgen Del Rocio
  • 이스라엘
      • Haifa, 이스라엘, 31096
        • 모집하지 않고 적극적으로
        • Rambam Medical Center
      • Haifa, 이스라엘, 3436212
        • 모집하지 않고 적극적으로
        • Carmel Medical Center
      • Jerusalem, 이스라엘, 91120
        • 모집하지 않고 적극적으로
        • Hadassah Medical Center
      • Ramat Gan, 이스라엘, 52621
        • 모집하지 않고 적극적으로
        • Sheba Medical Center
      • Tel Aviv, 이스라엘, 64239
        • 모집하지 않고 적극적으로
        • Tel Aviv Sourasky Medical Center
  • 일본
      • Chiba, 일본, 296-8602
        • 완전한
        • Kameda Medical Center
      • Fukuoka, 일본, 814-0180
        • 완전한
        • Fukuoka University Hospital
      • Gifu, 일본, 503-8502
        • 완전한
        • Ogaki Municipal Hospital
      • Hokkaido, 일본, 006-8555
        • 완전한
        • Teine Keijinkai Hospital
      • Kobe, 일본, 650 0047
        • 완전한
        • Kobe City Medical Center General Hospital
      • Koshigaya, 일본, 343-8555
        • 완전한
        • Dokkyo Medical University Saitama Medical Center
      • Kumamoto, 일본, 860-8556
        • 완전한
        • Kumamoto University Hospital
      • Kurashiki, 일본, 710-8602
        • 완전한
        • Kurashiki Central Hospital
      • Matsumoto, 일본, 399-8701
        • 완전한
        • National Hospital Organization Matsumoto Medical Center
      • Okayama, 일본, 701-1192
        • 완전한
        • National Hospital Organization Okayama Medical Center
      • Osaka, 일본, 543 8555
        • 완전한
        • Japanese Red Cross Osaka Hospital
      • Shiwa-gun, 일본, 028-3695
        • 완전한
        • Iwate Medical University Hospital
      • Ōtake, 일본, 739-0696
        • 모집하지 않고 적극적으로
        • National Hospital Organization Hiroshima-Nishi Medical Center
  • 중국
      • Beijing, 중국, 100191
        • 완전한
        • Peking University Third Hospital
      • Guangzhou, 중국, 510060
        • 모집하지 않고 적극적으로
        • Sun Yat Sen University Cancer Center
      • Hangzhou, 중국, 310003
        • 모집하지 않고 적극적으로
        • The 1St Affiliated Hospital of Medical College Zhejiang University
      • Hangzhou, 중국, 310003
        • 모집하지 않고 적극적으로
        • The 1st Affiliated Hospital Of Medical College Zhejiang University 1
      • Suzhou, 중국, 215006
        • 모집하지 않고 적극적으로
        • First Affiliated Hospital SooChow University
      • Tianjin, 중국, 300320
        • 모집하지 않고 적극적으로
        • Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science
      • Xi'an, 중국, 710004
        • 완전한
        • The Second Affiliated Hospital of Xi'an Jiaotong University
      • Xi'an, 중국, 710063
        • 완전한
        • The First Affiliated Hospital of Xian Jiaotong University
  • 폴란드
      • Gdansk, 폴란드, 80 214
        • 모집하지 않고 적극적으로
        • Uniwersyteckie Centrum Kliniczne
      • Gliwice, 폴란드, 44102
        • 완전한
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz w Gliwicach
      • Poznan, 폴란드, 60-569
        • 모집하지 않고 적극적으로
        • Uniwersytecki Szpital Kliniczny w Poznaniu
      • Warsaw, 폴란드, 02-781
        • 완전한
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Wroclaw, 폴란드, 50 367
        • 모집하지 않고 적극적으로
        • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
  • 프랑스
      • Créteil, 프랑스, 94000
        • 모집하지 않고 적극적으로
        • CHU Henri Mondor
      • Lyon, 프랑스, 69002
        • 모집하지 않고 적극적으로
        • Hospices Civils de Lyon HCL
      • Montpellier, 프랑스, 34295
        • 모집하지 않고 적극적으로
        • CHU de Montpellier Hopital Saint Eloi
      • Nantes, 프랑스, 44093
        • 모집하지 않고 적극적으로
        • C.H.U. Hotel Dieu - France
      • Pessac, 프랑스, 33604
        • 모집하지 않고 적극적으로
        • CHU de Bordeaux - Hospital Haut-Leveque
      • Toulouse, 프랑스, 31059
        • 모집하지 않고 적극적으로
        • Pôle IUC Oncopole CHU

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Documented initial diagnosis of multiple myeloma according to international myeloma working group (IMWG) diagnostic criteria
  • Part 3: Measurable disease cohort A, cohort B, cohort C and cohort D: multiple myeloma must be measurable by central laboratory assessment; Cohort E: Multiple myeloma must be measurable by local laboratory assessment
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (beta human chorionic gonadotropin [hCG]) or urine
  • Willing and able to adhere to the prohibitions and restrictions specified in this protocol

Exclusion Criteria:

  • Part 3 only: Cohort A and Cohort C only: exposed to a CAR-T or T cell redirection therapy at any time. Cohort B, Cohort D and Cohort E: T cell redirection therapy within 3 months
  • Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy
  • Received a cumulative dose of corticosteroids equivalent to >= 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication)
  • Stroke or seizure within 6 months prior to signing the informed consent form (ICF)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part 3: Cohort A (Talquetamab)

Cohort A will enroll participants with multiple myeloma who have previously received greater than or equal to (>=) 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. All participants (ongoing and those who are in follow-up) will transition to open-label extension (OLE) phase and will continue to receive the study treatment. Upon approval of amendment 19 and notification from the sponsor, participants will transition to the long-term extension (LTE) and will continue to receive study treatment.
의약품: Talquetamab

Talquetamab will be administered SC until disease progression.

다른 이름들:
  • JNJ-64407564
실험적: Part 3: Cohort B (Talquetamab)

Cohort B will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. All participants (ongoing and those who are in follow-up) will transition to OLE phase and will continue to receive the study treatment. Upon approval of amendment 19 and notification from the sponsor, participants will transition to the LTE and will continue to receive study treatment.
의약품: Talquetamab

Talquetamab will be administered SC until disease progression.

다른 이름들:
  • JNJ-64407564
실험적: Part 3: Cohort C (Talquetamab)

Cohort C will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. All participants (ongoing and those who are in follow-up) will transition to OLE phase and will continue to receive the study treatment. Upon approval of amendment 19 and notification from the sponsor, participants will transition to the LTE and will continue to receive study treatment.
의약품: Talquetamab

Talquetamab will be administered SC until disease progression.

다른 이름들:
  • JNJ-64407564
실험적: Part 3: Cohort D (Talquetamab)

Cohort D will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. Participants in this cohort will receive tocilizumab prophylaxis for cytokine release syndrome (CRS) including all outpatient dosing. Participants will transition to OLE upon communication by the sponsor. Upon approval of amendment 19 and notification from the sponsor, participants will transition to the LTE and will continue to receive study treatment.
의약품: Talquetamab

Talquetamab will be administered SC until disease progression.

다른 이름들:
  • JNJ-64407564
실험적: Part 3: Cohort E (Talquetamab)

Cohort E will enroll participants with multiple myeloma who have previously received at least 1 proteasome inhibitor (PI), 1 immunomodulatory imide drug (IMiD), and 1 anti-cluster of differentiation 38 (CD38) monoclonal antibody.

Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study. Participants will receive tocilizumab prophylaxis for CRS with consolidated priming dose schedules as well as possible transition to outpatient priming dosing transition to OLE upon communication by the sponsor. Upon approval of amendment 19 and notification from the sponsor, participants will transition to the LTE and will continue to receive study treatment.
의약품: Talquetamab

Talquetamab will be administered SC until disease progression.

다른 이름들:
  • JNJ-64407564

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Response Rate (ORR)
기간: Up to 2 years and 10 months

ORR is defined as the proportion of participants who have a partial response (PR) or better according to the international myeloma working group (IMWG) criteria.
Up to 2 years and 10 months

2차 결과 측정

결과 측정
측정값 설명
기간
Duration of Response (DOR)
기간: Up to 2 years and 10 months

DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG criteria, or death due to PD, whichever occurs first.
Up to 2 years and 10 months
Very Good Partial Response (VGPR) or Better Rate
기간: Up to 2 years and 10 months

VGPR or better rate is defined as the percentage of patients who achieve a VGPR or better according to IMWG response criteria.
Up to 2 years and 10 months
Complete Response (CR) or Better Rate
기간: Up to 2 years and 10 months

CR or better rate is defined as the percentage of patients who achieve CR or better according to IMWG response criteria.
Up to 2 years and 10 months
Stringent Complete Response (sCR) Rate
기간: Up to 2 years and 10 months

sCR rate is defined as the percentage of patients who achieve sCR according to IMWG response criteria.
Up to 2 years and 10 months
Time to Response (TTR)
기간: Up to 2 years and 10 months

TTR is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.
Up to 2 years and 10 months
Progression-Free Survival (PFS)
기간: Up to 2 years and 10 months

PFS is defined as time from date of first dose of study drug to date of first documented PD, per IMWG criteria, or death due to any cause, whichever occurs first.
Up to 2 years and 10 months
Overall Survival (OS)
기간: Up to 2 years and 10 months

OS is defined as the time from the date of first dose of study drug to the date of the participant's death.
Up to 2 years and 10 months
Minimal Residual Disease (MRD) Negative Rate
기간: Up to 2 years and 10 months

MRD negativity rate is measured only for participants who achieve at least a CR but is reported based on all treated similar to the other response data.
Up to 2 years and 10 months
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
기간: Up to 2 years and 10 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Up to 2 years and 10 months
Number of Participants with Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability
기간: Up to 2 years and 10 months

An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Up to 2 years and 10 months
Number of Participants with AEs by Severity
기간: Up to 2 years and 10 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
Up to 2 years and 10 months
Number of Participants with Abnormalities in Clinical Laboratory Values
기간: Up to 2 years and 10 months

Number of participants with abnormalities in clinical laboratory values (such as hematology, serum chemistry and coagulation) will be reported.
Up to 2 years and 10 months
Serum Concentration of Talquetamab
기간: Up to 2 years and 10 months

Serum samples will be analyzed to determine concentrations of talquetamab.
Up to 2 years and 10 months
Number of Participants with Talquetamab Antibodies
기간: Up to 2 years and 10 months

Antibodies to talquetamab will be assessed to evaluate potential immunogenicity.
Up to 2 years and 10 months
Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC QLQ-C30)
기간: Baseline up to 2 years and 10 months

The EORTC- QLQ-Core-30 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.
Baseline up to 2 years and 10 months
Change from Baseline in HRQoL as Assessed by EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L)
기간: Baseline up to 2 years and 10 months

The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). The scores for the 5 separate questions are categorical and cannot be analyzed as cardinal numbers.
Baseline up to 2 years and 10 months
Change from Baseline in HRQoL as Assessed by Patient Global Impression of Severity (PGIS)
기간: Baseline up to 2 years and 10 months

The PGIS is a single item that assesses severity of the participant's health state, on a 5-point verbal rating scale. Score ranges from 1 (None) to 5 (Very Severe).
Baseline up to 2 years and 10 months
Overall Response Rate (ORR) in Participants with High-risk Molecular Features
기간: Up to 2 years and 10 months

ORR in participants with high risk is defined as the overall response rate among the high risk molecular subgroups or other high-risk molecular subtypes.
Up to 2 years and 10 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Janssen Research & Development, LLC

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 2월 1일

기본 완료 (추정된)

2027년 6월 30일

연구 완료 (추정된)

2029년 3월 30일

연구 등록 날짜

최초 제출

2020년 11월 16일

QC 기준을 충족하는 최초 제출

2020년 11월 16일

처음 게시됨 (실제)

2020년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • CR108920
  • 2017-002400-26 (EudraCT 번호)
  • TALMMY1001-PT3 (기타 식별자: Janssen Research & Development, LLC)
  • 2017 (미국 NIH 보조금/계약)
  • 2023-504581-29-00 (레지스트리 식별자: EUCT number)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다